Guggenheim Initiates Coverage On Voyager Therapeutics with Buy Rating, Announces Price Target of $22
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Voyager Therapeutics (NASDAQ:VYGR) with a Buy rating and a price target of $22.
March 26, 2024 | 10:39 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim analyst Debjit Chattopadhyay has initiated coverage on Voyager Therapeutics with a Buy rating and set a price target of $22.
The initiation of coverage by a reputable analyst with a Buy rating and a significant price target suggests a positive outlook for Voyager Therapeutics. This endorsement could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100